Is it possible to influence on antibiotic prescription habits?;Er det mulig a pâvirke bruken av antibiotika?

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 14, 1997, Pages 2056-2059

  Berild, Dag ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG COST; DRUG UTILIZATION; ECONOMICS; HEALTH ECONOMICS; HUMAN; NORWAY; PRESCRIPTION; STATISTICS; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; DRUG COSTS; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; ECONOMICS, HOSPITAL; HOSPITALS, UNIVERSITY; HUMANS; NORWAY; PRESCRIPTIONS, DRUG;

EID: 0031591191     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gundersen SG. Resistensproblemer i u-land - bruk og misbruk av antiinfektiva. Tidsskr Nor Lajgeforen 1992; 112: 2741-6.
2. Godai T. Mikrobene slâr tilbake. Tidsskr Nor Laageforen 1994; 114: 551.
3. Cohen ML. Epidemiology of drug resistance: implications fora post-antimicrobial era. Science 1992; 257: 1050-5.
4. Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 1993; 14: 376-82.
5. Tomasz A. Special report. Multiple-antibioticresistant pathogenic bacteria. A report on the Rockefeller University workshop. N Engl J Med 1994; 330: 1247-51.
6. O'Brien TF. Global surveillance of antibiotic resistance. N Engl J Med 1992; 326: 339-40.
7. Espersen F, Frimodt-M011er N. Kämpen mot mikroberne - et international anliggende. Ugeskr Laegerl996; 158:251.
8. Seppala H, Nissinen A, Jervinen H, Houvinen S, Henriksson T, Herva E et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326: 292-7.
9. Andersen BM, Almdahl SM, S0rlie D, Hotvedt R, Backer-Christensen J, Beck Nicolaysen R et al. Enterobacter cloacae-infeksjoner ved Regionsykehuset i Troms0. Tidsskr Nor Laegeforen 1990; 110:342-7.
10. Gamme C. Okritisk bruk av penicillin orsak till resistensutvekling hos pneumokocker. Läkartidningen 1992; 89: 757-8.
11. 0ydvin K, red. Legemiddelforbruket i Norge 1991-1995. Oslo: Norsk Medisinaidepot AS, 1996.
12. Ringertz S, Kronvall G. Increased use of erythromycin causes resistance in Haemophilus influenzae. Scand J Infect Dis 1987; 19: 247-56.
13. Kristinsson KG. Multiresistenta bakterier i nordisk perspektiv. Nord Med 1995; 110: 42-4.
14. Kling PA, 0stensson R, Granstnam S, Burman LG. A 7-year of drug resistance in aerobic and anaerobic fecal bacteria of surgical inpatients: clinical relevance to local antibiotic consumption. Scand J Infect Dis 1989; 21: 589-96.
15. Murray B, Rensimer ER, Du Pont HL. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim-sulfametoxazole. N Engl J Med 1982; 306: 130-5.
16. Richard P, Delangle M-H, Merrien D. Barille S. Reyneaud A, Minozzi C el al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994; 19: 54-9.
17. North D. Controlling the cost of antibiotic resistance. Clin Ther 1993; 15: 3-11.
18. Friis H, Bro F, Mabeck CE, Vejlsgaard R. Changes in prescription of antibiotics in general practice in relation to different strategies for drug information. Dan Med Bull 1991; 38: 380-2.
19. Friis H, Bro F, Mabeck CE, Vejlsgaard R. An information campaign - an important measure in controlling the use of antibiotics. J Antimicrob Chemother 1989; 24: 993-9.
20. Friis H, Bro F, Riewerts Eriksen N, Mabeck CE, Vejlsgaard R. The effect of reimbursement on the use of antibiotics. Scand J Prim Health Care 1993; 11: 247-51.
21. Salama S, Rotstein C, Mandell L. A multidisciplinary hospital-based antimicrobial use program: impact on hospital pharmacy expenditures and drug use. Can J Infect Dis 1996; 7: 104-9.
22. Kolmos HJ. Restriktiv antibiotikapolitik forebygger hospitalsinfektioner. Ugeskr Lasger 1994; 156: 2053.
23. Price DJE, Sleigh JD. Control of infection due to Klebsiella aerogenes in a neurosurgical unit by withdrawal of all antibiotics. Lancet 1979; 2: 1213-5.
24. Kerr JR, Barr JG, Smyth ETM, O'Hare J, Bell PM, Callender ME. Antibiotic pharmacoeconomics: an attempt to find the real cost of hospital antibiotic prescribing. Ulster Med J 1993; 62: 50-7.
25. Davey P. Pharmacoeconomics of appropriate antimicrobial use. Diagn Microbiol Infect Dis 1995; 22: 225-9.
26. Manzo J, Amodio-Groton MA, Kleinmann K. Antibiotic cost control measures in a hospital pharmacy. Clin Ther 1993; 15: 37-43.
27. Murray B. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis 1991; 163: 1185-94.
28. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065-74.
29. Murray BE Can antibiotic resistance be controlled? N Engl J Med 1994; 330: 1229-30.
30. Törling J, Örtqvist A. Bredspektrum antibiotika vid pneumoni. Användningen ökar oroande. Läkartidningen 1994; 91: 4516-7.
31. Nilsson-Ehle I, Cars O. Skerp indikationerne for makrolidbehandling. Överanvänding är en ekologisk risk. Läkartidningen 1994; 91: 4363-5.
32. Berild D, Kolmos HJ, Kjersem HJ, Sjursen H. Rasjonell antibiotikabehandling. Oslo: Universitetsforlaget, 1996: 12-4. O